After identifying two biomarker candidates that changed with treatment in the blood of Fmr1 KO mice, we asked whether any of the candidates identified by the BONLAC screens were differentially expressed in easily accessible FXS patient tissue. Here, FMR1 is linked to fragile X syndrome.